-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 26, the sixth batch of insulin special collection was officially opened in Shanghai.
This collection covers the second- and third-generation insulins commonly used in clinical practice, involving 11 companies and 16 generic varieties, and the average price of the products to be selected is reduced by 48 %, it is estimated that 9 billion yuan can be saved every year, which will bring good news to over 140 million diabetic patients in China
.
Judging from the results of the proposed selection, among the domestic manufacturers, all of the five competing products of Tonghua Dongbao, the second-generation insulin leader, are proposed to be selected, with an average decrease of 41%; all of the six competing products of the third-generation insulin head company Ganli Pharmaceutical Co.
, Ltd.
are proposed to be selected, which is a high decline.
Reached 72%; Dongyang Sunshine Pharmaceutical's insulin glargine, which had just been approved, was also successfully selected
.
In addition, Tianmai Biology, Hisun Pharmaceutical, and Dongyang Sunshine have also won the bid for their products
.
Among the import manufacturers, the three major multinational giants, Novo Nordisk, Sanofi, and Eli Lilly, are also actively fighting.
The number of winning bidders is 7, 5, and 2, respectively, with an average decrease of 41%, 52%, and 44.
%
.
On the whole, the price cuts for this special collection of insulin are relatively mild.
Among them, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection reported 18.
89 yuan, a drop of more than 73%, followed by the domestic company Ganli Pharmaceutical, its Insulin aspart injection reported 19.
98 yuan, a drop of more than 72%
.
However, compared with Eli Lilly, Gan Li Pharmaceuticals has significantly less pressure to cut prices
.
Previously, the company stated in its 2020 annual report that compared with imported insulin analogues, the company's products have a clear price advantage
.
According to statistics, the company's product prices are on average about 20% lower than similar imported products
.
According to PDB data, in the Chinese insulin market, the market shares of Novo Nordisk, Sanofi, and Eli Lilly were originally divided into 48.
5%, 25.
8%, and 10.
3%.
The total of the three is about 75% of the entire market
.
The centralized procurement of Chinese manufacturers clearly breaks through, and is expected to have a certain impact on the three multinational pharmaceutical companies.
In the future, the market size of import manufacturers will be further compressed
.
Regarding the impact of the future market, the industry expects that after this centralized procurement, local companies will have less pressure to reduce prices relative to imported pharmaceutical companies, and will retain more profit margins.
It is expected to accelerate domestic substitution and further "divide" the market share of foreign companies.
.
For example, Tonghua Dongbao stated in the announcement that this centralized procurement will help the company further expand the sales of related products, especially insulin analog products, accelerate product access, increase market share, and enhance the company’s brand influence.
And the future long-term development has a positive impact
.
However, some people in the industry believe that although the market size of imported manufacturers will decline under the influence of centralized procurement, they are still expected to be competitive because they have a relatively large advantage
.
In addition, import manufacturers are also accelerating the launch of new drugs
.
For example, Sanofi is actively developing a compound preparation of basal insulin and GLP-1.
The company stated at the November International Import Expo that the Phase III clinical China study of the innovative drug iGlarLixi (insulin glargine lisnatide injection) has reached The primary efficacy endpoint is expected to be approved for marketing in China soon; on October 28, Novo Nordisk’s "Insulin Deglulam and Liraglutide Injection (Novozymes)" was also approved for marketing in China.
The product is a compound preparation of basal insulin Degu and GLP-1 receptor agonist.
It is injected once a day to reduce the risk of hypoglycemia
.
It is foreseeable that, regardless of whether domestic manufacturers or imported manufacturers, competition in the market will be more intense in the future, and under the trend of centralized procurement and price reduction, it will be a boon for patients after all
.
This collection covers the second- and third-generation insulins commonly used in clinical practice, involving 11 companies and 16 generic varieties, and the average price of the products to be selected is reduced by 48 %, it is estimated that 9 billion yuan can be saved every year, which will bring good news to over 140 million diabetic patients in China
.
Judging from the results of the proposed selection, among the domestic manufacturers, all of the five competing products of Tonghua Dongbao, the second-generation insulin leader, are proposed to be selected, with an average decrease of 41%; all of the six competing products of the third-generation insulin head company Ganli Pharmaceutical Co.
, Ltd.
are proposed to be selected, which is a high decline.
Reached 72%; Dongyang Sunshine Pharmaceutical's insulin glargine, which had just been approved, was also successfully selected
.
In addition, Tianmai Biology, Hisun Pharmaceutical, and Dongyang Sunshine have also won the bid for their products
.
Among the import manufacturers, the three major multinational giants, Novo Nordisk, Sanofi, and Eli Lilly, are also actively fighting.
The number of winning bidders is 7, 5, and 2, respectively, with an average decrease of 41%, 52%, and 44.
%
.
On the whole, the price cuts for this special collection of insulin are relatively mild.
Among them, Eli Lilly’s protamine zinc recombinant insulin lispro mixed injection reported 18.
89 yuan, a drop of more than 73%, followed by the domestic company Ganli Pharmaceutical, its Insulin aspart injection reported 19.
98 yuan, a drop of more than 72%
.
However, compared with Eli Lilly, Gan Li Pharmaceuticals has significantly less pressure to cut prices
.
Previously, the company stated in its 2020 annual report that compared with imported insulin analogues, the company's products have a clear price advantage
.
According to statistics, the company's product prices are on average about 20% lower than similar imported products
.
According to PDB data, in the Chinese insulin market, the market shares of Novo Nordisk, Sanofi, and Eli Lilly were originally divided into 48.
5%, 25.
8%, and 10.
3%.
The total of the three is about 75% of the entire market
.
The centralized procurement of Chinese manufacturers clearly breaks through, and is expected to have a certain impact on the three multinational pharmaceutical companies.
In the future, the market size of import manufacturers will be further compressed
.
Regarding the impact of the future market, the industry expects that after this centralized procurement, local companies will have less pressure to reduce prices relative to imported pharmaceutical companies, and will retain more profit margins.
It is expected to accelerate domestic substitution and further "divide" the market share of foreign companies.
.
For example, Tonghua Dongbao stated in the announcement that this centralized procurement will help the company further expand the sales of related products, especially insulin analog products, accelerate product access, increase market share, and enhance the company’s brand influence.
And the future long-term development has a positive impact
.
However, some people in the industry believe that although the market size of imported manufacturers will decline under the influence of centralized procurement, they are still expected to be competitive because they have a relatively large advantage
.
In addition, import manufacturers are also accelerating the launch of new drugs
.
For example, Sanofi is actively developing a compound preparation of basal insulin and GLP-1.
The company stated at the November International Import Expo that the Phase III clinical China study of the innovative drug iGlarLixi (insulin glargine lisnatide injection) has reached The primary efficacy endpoint is expected to be approved for marketing in China soon; on October 28, Novo Nordisk’s "Insulin Deglulam and Liraglutide Injection (Novozymes)" was also approved for marketing in China.
The product is a compound preparation of basal insulin Degu and GLP-1 receptor agonist.
It is injected once a day to reduce the risk of hypoglycemia
.
It is foreseeable that, regardless of whether domestic manufacturers or imported manufacturers, competition in the market will be more intense in the future, and under the trend of centralized procurement and price reduction, it will be a boon for patients after all
.
